PE20020884A1 - 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico - Google Patents

4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico

Info

Publication number
PE20020884A1
PE20020884A1 PE2002000123A PE2002000123A PE20020884A1 PE 20020884 A1 PE20020884 A1 PE 20020884A1 PE 2002000123 A PE2002000123 A PE 2002000123A PE 2002000123 A PE2002000123 A PE 2002000123A PE 20020884 A1 PE20020884 A1 PE 20020884A1
Authority
PE
Peru
Prior art keywords
indan
benzamide
fluoro
hypertension
angina
Prior art date
Application number
PE2002000123A
Other languages
English (en)
Inventor
Ramalinga Dharanipragada
Alena Safarova
Paulus Wohlfart
Teri Suzuki
Armin Walser
Hartmut Strobel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20020884A1 publication Critical patent/PE20020884A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL USO DE 4-FLUORO-N-INDAN-2-IL-BENZAMIDA DE FORMULA I, PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, ANGINA DE PECHO, CARDIOPATIA ISQUEMICA, ANGINA DE PRINZMETAL, SINDROME CORONARIO AGUDO, INSUFICIENCIA CARDIACA, INFARTO DE MIOCARDIO, TROMBOSIS, ENFERMEDAD OCLUSIVA DE LAS ARTERIAS PERIFERICAS, DISFUNCION ENDOTELIAL, ATEROSCLEROSIS, RESTENOSIS, HIPERTENSION, HIPERTENSION PULMONAR, HIPERTENSION RENOVASCULAR, GLOMERULONEFRITIS, DISFUNCION ERECTIL, ARRITMIA VENTRICULAR, DIABETES, NEFROPATIA, RETINOPATIA, ANGIOGENESIS, ASMA BRONQUIAL, CIRROSIS HEPATICA, OSTEOPOROSIS. TAMBIEN SE REFIERE A UNA PREPARACION FARMACEUTICA QUE COMPRENDE EL COMPUESTO DE FORMULA I
PE2002000123A 2001-02-13 2002-02-13 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico PE20020884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01102852 2001-02-13

Publications (1)

Publication Number Publication Date
PE20020884A1 true PE20020884A1 (es) 2002-11-25

Family

ID=8176423

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000123A PE20020884A1 (es) 2001-02-13 2002-02-13 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico

Country Status (34)

Country Link
US (3) US6617359B2 (es)
EP (1) EP1361882B1 (es)
JP (1) JP4317689B2 (es)
KR (1) KR101017531B1 (es)
CN (1) CN100553631C (es)
AT (1) ATE344669T1 (es)
AU (1) AU2002253009B2 (es)
BG (1) BG66065B1 (es)
BR (1) BR0207178A (es)
CA (1) CA2437966C (es)
CY (1) CY1106278T1 (es)
CZ (1) CZ20032154A3 (es)
DE (1) DE60215919T2 (es)
DK (1) DK1361882T3 (es)
EE (1) EE05302B1 (es)
ES (1) ES2274025T3 (es)
HK (1) HK1062140A1 (es)
HR (1) HRP20030646A2 (es)
HU (1) HUP0302845A3 (es)
IL (2) IL157208A0 (es)
MX (1) MXPA03006841A (es)
MY (1) MY135778A (es)
NO (1) NO333522B1 (es)
NZ (1) NZ527469A (es)
PE (1) PE20020884A1 (es)
PL (1) PL363452A1 (es)
PT (1) PT1361882E (es)
RS (1) RS51645B (es)
RU (1) RU2308946C2 (es)
SI (1) SI1361882T1 (es)
SK (1) SK286513B6 (es)
TW (1) TWI241190B (es)
WO (1) WO2002064146A1 (es)
ZA (1) ZA200305412B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
AR035431A1 (es) * 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
PT1554240E (pt) 2002-10-21 2009-06-17 Janssen Pharmaceutica Nv Tetralinas e indanos substituídos e sua utilização
WO2004047743A2 (en) * 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
WO2005009941A1 (en) * 2003-07-03 2005-02-03 Eli Lilly And Company Indane derivates as muscarinic receptor agonists
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
EP3138566B1 (en) * 2003-11-17 2022-01-26 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
WO2006055511A2 (en) * 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
US7612080B2 (en) 2004-11-19 2009-11-03 Cincinnati Children's Hospital Medical Center GTPase inhibitors and use thereof for controlling platelet hyperactivity
US20060185492A1 (en) 2005-02-18 2006-08-24 Francois Chianese Shoulder bushing for saw blades
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US7795101B2 (en) * 2006-04-03 2010-09-14 United Microelectronics Corp. Method of forming a MOS transistor
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
KR101349187B1 (ko) * 2006-12-05 2014-01-10 (주)아모레퍼시픽 지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
CA2701695A1 (en) * 2007-10-09 2009-04-16 Novartis Ag Pharmaceutical formulation of valsartan
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
BR112012033341B1 (pt) 2010-06-30 2022-08-23 Cyclerion Therapeutics, Inc Estimulantes de sgc
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
LT2970243T (lt) 2013-03-15 2020-03-10 Cyclerion Therapeutics, Inc. Sgc stimuliatoriai
EP3092231B1 (en) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
IL263996B2 (en) 2016-07-07 2024-03-01 Ironwood Pharmaceuticals Inc Solid configurations of the SGC promoter
WO2018009596A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) * 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
AU2001264977B2 (en) * 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
AR035431A1 (es) * 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
US7338956B2 (en) * 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
NO20033546D0 (no) 2003-08-11
US20040019114A1 (en) 2004-01-29
BR0207178A (pt) 2004-03-30
KR20030074809A (ko) 2003-09-19
MXPA03006841A (es) 2003-11-13
HK1062140A1 (en) 2004-10-21
AU2002253009B2 (en) 2006-09-14
CY1106278T1 (el) 2011-10-12
BG107994A (bg) 2004-08-31
EE200300368A (et) 2003-10-15
ES2274025T3 (es) 2007-05-16
CN1496264A (zh) 2004-05-12
NZ527469A (en) 2005-04-29
DE60215919T2 (de) 2007-05-31
RS51645B (en) 2011-10-31
WO2002064146A1 (en) 2002-08-22
PL363452A1 (en) 2004-11-15
RU2003127750A (ru) 2005-03-10
EE05302B1 (et) 2010-06-15
JP4317689B2 (ja) 2009-08-19
HUP0302845A2 (hu) 2003-12-29
KR101017531B1 (ko) 2011-02-28
TWI241190B (en) 2005-10-11
US20030022939A1 (en) 2003-01-30
SI1361882T1 (sl) 2007-02-28
MY135778A (en) 2008-06-30
PT1361882E (pt) 2007-01-31
IL157208A0 (en) 2004-02-19
ATE344669T1 (de) 2006-11-15
US6812253B2 (en) 2004-11-02
NO20033546L (no) 2003-09-24
EP1361882B1 (en) 2006-11-08
SK286513B6 (sk) 2008-12-05
NO333522B1 (no) 2013-07-01
HUP0302845A3 (en) 2005-11-28
US20050054729A1 (en) 2005-03-10
CA2437966A1 (en) 2002-08-22
DK1361882T3 (da) 2007-03-12
SK10112003A3 (sk) 2004-01-08
JP2004518713A (ja) 2004-06-24
RU2308946C2 (ru) 2007-10-27
IL157208A (en) 2009-09-22
DE60215919D1 (de) 2006-12-21
BG66065B1 (bg) 2011-01-31
CA2437966C (en) 2011-06-14
CN100553631C (zh) 2009-10-28
EP1361882A1 (en) 2003-11-19
HRP20030646A2 (en) 2005-06-30
CZ20032154A3 (cs) 2004-05-12
RS61703A (en) 2006-12-15
US6617359B2 (en) 2003-09-09
ZA200305412B (en) 2004-09-02
US7202278B2 (en) 2007-04-10

Similar Documents

Publication Publication Date Title
PE20020884A1 (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico
UY27164A1 (es) 1, 2, 3, 4- tetrahidronaftil aminas aciladas y su uso como farmacos
CO5621286A2 (es) Combinacion de un inhibidor de dpp iv y un compuesto cardiovascular
UY27965A1 (es) Derivados heterocíclicos
BR0207197A (pt) 6,7,8,9-tetraidro-5h-benzocicloeptenil aminas aciladas e seu uso como agente farmacêutico
ECSP10010017A (es) Activadores de guanilato ciclasas solubles
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
SV2006002288A (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) ref. p-sv-79054/ug
CR7074A (es) Derivados de mercaptoacetylamida y proceso para su preparacion y uso
DOP2002000481A (es) Derivados de acido acetico
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
PA8661701A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
UY28115A1 (es) Derivados del acido isoftalico
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
JP2003267863A5 (es)
DK1311486T3 (da) Anvendelser af thaliporphin eller dets derivater til behandling af hjertesygdomme og fremstilling af samme
DOP2003000700A (es) Derivados heterociclicos
PA8552101A1 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas y su uso como farmacos
PA8552001A1 (es) 1,2,3,4-tetrahidronaftil aminas aciladas y su uso como farmacos
ECSP993240A (es) Preparaciones de combinacion farmaceutica

Legal Events

Date Code Title Description
FC Refusal